FDA Approves Zyn Pouches For Sale

FDA officially authorizes Zyn nicotine pouches for sale following health review
The U.S. Food and Drug Administration formally authorized Zyn nicotine pouches for sale after conducting an "extensive scientific review" about their safety.
FDA approves 20 ZYN nicotine pouches after thorough' safety review
The U.S. Food and Drug Administration (FDA) has approved 20 ZYN nicotine "pouch" products for sale after what it called "a thorough review." These nicotine
FDA authorizes sale of Zyn nicotine pouches, saying public health benefits outweigh risk
Zyn and the retailers who sell the product have run afoul of regulators in recent years. The FDA in April of last year warned 119 retailers to stop selling Zyn to underage people, and the company was ordered to pay $1.2 million last year for violating Washington, D.C.’s smokeless tobacco ban.
FDA Approves Marketing of Nicotine Pouches
Following an extensive scientific review, the U.S. Food and Drug Administration has authorized the marketing of 20 ZYN nicotine pouch products. Nicotine pouches -- small synthetic fiber pouches containing nicotine -- are designed to be placed between a person's gum and lip.
FDA authorizes Zyn nicotine pouches, cites lower risk than cigarettes
The FDA authorized the marketing of 20 Zyn products on Thursday, marking the first allowance for the fast-growing nicotine pouches.
FDA OKs sales of Zyn nicotine pouches, citing health benefits for adult smokers
Federal health officials are backing the health benefits of nicotine pouches, ruling that Philip Morris International’s Zyn can help adult smokers cut back or quit cigarettes
FDA Authorizes All ZYN Nicotine Pouch Products Marketed By Swedish Match In U.S.
The U.S. Food and Drug Administration has authorized all ZYN Nicotine Pouch Products Currently Marketed by Swedish Match, a
For first time, FDA approves marketing of nicotine pouch products
The U.S. Food and Drug Administration on Thursday okayed the marketing of 20 Zyn nicotine pouch products after undertaking an extensive scientific review of them.
Hosted on MSN4h
Arrowhead’s plozasiran set for FDA review as Tryngolza challenge looms
An FDA approval later this year for Arrowhead’s plozasiran in FCS would put it in direct competition with Ionis’ Tryngolza.
JD Supra5h
Drugs and Biologics at FDA: Reflections on 2024 Activity Shed Light on the Road Ahead
With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...
FiercePharma10d
Breaking down the 55 new drug approvals of 2024
A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods g | ...
Cure Today6d
FDA Grants Priority Review to Sunvozertinib for EGFR Exon20+ NSCLC
The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.
JD Supra2h
Trump’s FDA and USDA: Five Key Issues To Watch in 2025
The Trump administration’s food regulatory agenda will come into sharper focus once nominees for the U.S. Department of Health and Human ...
Hosted on MSN1h
CergenX wins FDA breakthrough designation for neonatal EEG assessment tool
Trained on large databases of brain data among newborns, CergenX’s Wave device uses AI to help with earlier detection of ...
Outgoing FDA chief flags online weight loss drug dangers
Current laws and regulations are not enough to protect Americans from the risks of compounded versions of popular weight loss ...
Dayton Daily News7d
FDA reviews reports of dog illnesses, death connected to arthritis drug
The U.S. Food and Drug Administration is reviewing reports that more than 1,000 dogs died in an 18-month span after taking an arthritis drug called Librela.
Targeted Oncology13d
FDA Grants Priority Review to Sunvozertinib in EGFR+ NSCLC
The FDA granted priority review to sunvozertinib for the treatment of advanced NSCLC with EGFR exon 20 mutations, based on ...
FDA’s START and CoGenT pilot programmes: Streamlining rare disease drug approvals
These initiatives represent a way to accelerate access to treatments that have historically faced longer regulatory pathways.